Inscripta
Inscripta is a synthetic biology company that develops and commercializes genome engineering technologies, including the GenoScaler™ Platform and MADzyme™ nucleases, to enhance biomanufacturing processes.
Company Overview
Inscripta develops and commercializes synthetic biology products using advanced genome engineering technologies. The company is recognized for its focus on optimizing microbial strains for biomanufacturing, thereby pushing the boundaries of synthetic biology and genome manipulation.
GenoScaler™ Platform
Inscripta offers the GenoScaler™ Platform, an advanced technology dedicated to optimizing microbial strains for biomanufacturing. This platform allows for enhanced scalability and efficiency in the production of biologically derived materials, playing a critical role in sustainable biomanufacturing processes.
MAD7® Nuclease
The company provides the MAD7® Nuclease, which is part of their proprietary MADzyme™ nucleases. This technology is utilized for CRISPR-based genome editing, thus enabling precise and effective genetic modifications. Several MADzyme™ variants with improved properties are available through a broad, non-exclusive licensing program.
Strategic Acquisitions
To enhance its capabilities in sustainable biomanufacturing, Inscripta acquired Infinome Biosciences and Sestina Bio. These acquisitions have allowed the company to expand its technological resources and expertise in the field of genome engineering.
Partnerships and Collaborations
Inscripta partners with Bedoukian Research Inc. to develop and manufacture naturally produced ingredients utilizing the GenoScaler™ Platform. This collaboration exemplifies the company's commitment to combining innovative technologies to produce high-quality, sustainable biomanufacturing solutions.